Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 St-Denis Street, Montréal, QC H2X 0A9, Canada; Department of Psychiatry and Addiction, Faculty of Medicine, Université de Montréal, 2900 Édouard-Montpetit Boulevard, Montréal, QC H3T 1J4, Canada.
Research Center, Centre Hospitalier de l'Université de Montréal (CRCHUM), 900 St-Denis Street, Montréal, QC H2X 0A9, Canada; Department of Psychiatry and Addiction, Faculty of Medicine, Université de Montréal, 2900 Édouard-Montpetit Boulevard, Montréal, QC H3T 1J4, Canada; Department of Psychiatry and Behavioral science, College of Medicine and Health Sciences, United Arab Emirates University, Khalifa Bin Zayed Street, Tawam, Al Ain, Abu Dhabi, United Arab Emirates.
Pharmacol Biochem Behav. 2022 May;216:173376. doi: 10.1016/j.pbb.2022.173376. Epub 2022 Mar 31.
Cocaine use disorder (CUD) is associated with various cognitive deficits that impede patients' functionality, prognosis and therapeutic outcomes. New pharmacological treatments for CUD that could improve cognition are needed.
To explore whether cannabidiol (CBD) is superior to placebo to improve cognitive functioning in individuals with CUD.
We conducted an exploratory analysis of a single site, randomized, double-blind, placebo-controlled trial evaluating CBD's efficacy in reducing craving, cocaine use and relapse in individuals with CUD. Seventy-eight individuals diagnosed with CUD were randomized to receive either CBD (800 mg) or placebo for 92 days. We used the Cambridge Neuropsychological Test Automated Battery (CANTAB) to assess inhibition (Stop Signal Task; SST), risky decision making (Cambridge Gambling Task; CGT) and visual memory (Pattern Recognition Memory; PRM). This assessment was made on day 1, day 7 and at week 6. We controlled for sex, severity of dependence and baseline cognitive scores in our generalized estimating equation models.
Both groups performed similarly on the PRM (correct answers: p = 0.080), SST (stop signal reaction time: p = 0.644) and CGT (quality of decision making: p = 0.994; deliberation time: p = 0.507; delay aversion: p = 0.968; risk taking: p = 0.914) tests.
We found no evidence for 800 mg of CBD to be more efficacious than placebo for improving cognitive outcomes. Clinical trials evaluating pharmacological treatments for CUD should continue to be a research priority.
可卡因使用障碍（CUD）与各种认知缺陷有关，这些缺陷会阻碍患者的功能、预后和治疗效果。需要新的药理学治疗方法来改善 CUD 的认知功能。
探讨大麻二酚（CBD）是否优于安慰剂，以改善 CUD 患者的认知功能。
我们对一项单中心、随机、双盲、安慰剂对照试验进行了探索性分析，该试验评估了 CBD 对减少 CUD 个体的渴望、可卡因使用和复发的疗效。78 名被诊断为 CUD 的个体被随机分配接受 CBD（800mg）或安慰剂治疗 92 天。我们使用剑桥神经心理学测试自动化电池（CANTAB）评估抑制（停止信号任务；SST）、冒险决策（剑桥赌博任务；CGT）和视觉记忆（模式识别记忆；PRM）。这项评估在第 1 天、第 7 天和第 6 周进行。我们在广义估计方程模型中控制了性别、依赖严重程度和基线认知评分。
两组在 PRM（正确答案：p=0.080）、SST（停止信号反应时间：p=0.644）和 CGT（决策质量：p=0.994；审议时间：p=0.507；延迟厌恶：p=0.968；冒险：p=0.914）测试中的表现相似。
我们没有发现 800mg CBD 比安慰剂更能有效改善认知结果。评估 CUD 药物治疗的临床试验应继续成为研究重点。
